Urinary Incontinence – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Urinary Incontinence – Drugs In Development, 2024 report and make more profitable business decisions.
Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and kidney diseases. Treatment includes anticholinergics and topical estrogen.
The Urinary Incontinence drugs in development market research report provide comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Urinary Incontinence | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Urinary Incontinence therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Urinary Incontinence pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Urinary Incontinence treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncBio-Fd&C Co Ltd
Changchun Jinsai Pharmaceutical Co Ltd
Cook MyoSite Inc
Crystec Ltd
Exopharm Ltd
Innovacell Biotechnologie AG
Medipreneur Co Ltd
MUVON Therapeutics AG
MyoPax GmbH
Orgenesis Inc
Pfizer Inc
Profem GmbH
Rion Inc
Stanford University
Taiho Pharmaceutical Co Ltd
Theratome Bio Inc
Urovant Sciences Inc
Versameb AG
Viatris Inc
Wake Forest University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Urinary Incontinence reports